Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Enanta Pharmaceuticals (ENTA) Change in Taxes (2016 - 2025)

Enanta Pharmaceuticals' Change in Taxes history spans 12 years, with the latest figure at $31.9 million for Q2 2025.

  • For Q2 2025, Change in Taxes rose 7434.91% year-over-year to $31.9 million; the TTM value through Dec 2025 reached $33.3 million, up 4595.77%, while the annual FY2025 figure was $33.8 million, 3295.48% up from the prior year.
  • Change in Taxes reached $31.9 million in Q2 2025 per ENTA's latest filing, up from $1.4 million in the prior quarter.
  • In the past five years, Change in Taxes ranged from a high of $31.9 million in Q2 2025 to a low of -$8.5 million in Q4 2021.
  • Average Change in Taxes over 5 years is $3.1 million, with a median of $360500.0 recorded in 2024.
  • The largest YoY upside for Change in Taxes was 50970.0% in 2023 against a maximum downside of 14185.0% in 2023.
  • A 5-year view of Change in Taxes shows it stood at -$8.5 million in 2021, then surged by 99.82% to -$15000.0 in 2022, then soared by 4966.67% to $730000.0 in 2023, then crashed by 39.04% to $445000.0 in 2024, then surged by 7079.33% to $31.9 million in 2025.
  • Per Business Quant, the three most recent readings for ENTA's Change in Taxes are $31.9 million (Q2 2025), $1.4 million (Q1 2025), and $445000.0 (Q4 2024).